Why do my platelets continue to drop after taking venetoclax?

Venetoclax is a targeted therapy drug widely used to treat certain types of leukemia and lymphoma. However, one problem some patients may face while taking venetoclax is a steady decline in their platelet count. This phenomenon has attracted great attention from patients and doctors. So why does the use of venetoclax cause a sustained decrease in platelet counts?

First, we need to understand how Venexacla works. Veneclat inhibits B-cell lymphoma-2 (BCL-2) protein and promotes the apoptosis of cancer cells, thereby achieving the treatment of leukemia and lymphoma. However, this mechanism may have consequences for hematopoiesis in the bone marrow, including platelet production. Platelets are an important component of blood responsible for hemostasis. When their number decreases, patients may experience bleeding tendencies such as skin ecchymosis, gum bleeding, and nosebleeds.

Decreased platelet counts in patients treated with venetoclax are likely due to the drug's suppression of the hematopoietic function of the bone marrow. This condition may expose patients to certain risks during treatment. Therefore, patients and physicians should pay close attention to changes in platelet counts and take appropriate measures to manage them.

In response to a drop in platelet counts, patients should have regular blood tests to monitor changes in platelet levels. Once a significant decrease in platelet counts is noted, doctors may adjust the dose of venetoclax on a case-by-case basis or consider temporarily discontinuing the drug to prevent further reductions in platelet counts. In addition, for patients with severely low platelet counts, doctors may consider other adjuvant treatments, such as platelet transfusions, to mitigate the risk of bleeding and reduce the likelihood of complications.

It's important to note that while venetoclax may cause a drop in platelet counts, not all patients will experience this side effect. By regularly monitoring platelet levels and promptly adjusting treatment plans, most patients can effectively control platelet counts and ensure the safety and effectiveness of treatment.

Therefore, it is important for patients receiving venetoclax to understand and pay attention to changes in platelet counts. At the same time, maintaining good communication with the doctor and promptly reporting any symptoms of discomfort are the keys to ensuring smooth treatment.

References:

https://www.drugs.com/venclexta.html